CareCloud, Inc.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, VEEV has a market cap of 38.61B. Regarding current trading prices, MTBCP is priced at $26.91, while VEEV trades at $236.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas VEEV's P/E ratio is 54.98. In terms of profitability, MTBCP's ROE is +0.17%, compared to VEEV's ROE of +0.13%. Regarding short-term risk, MTBCP is less volatile compared to VEEV. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, GEHC has a market cap of 31.98B. Regarding current trading prices, MTBCP is priced at $26.91, while GEHC trades at $69.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas GEHC's P/E ratio is 14.67. In terms of profitability, MTBCP's ROE is +0.17%, compared to GEHC's ROE of +0.26%. Regarding short-term risk, MTBCP is less volatile compared to GEHC. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, GEHCV has a market cap of 25.46B. Regarding current trading prices, MTBCP is priced at $26.91, while GEHCV trades at $56.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas GEHCV's P/E ratio is N/A. In terms of profitability, MTBCP's ROE is +0.17%, compared to GEHCV's ROE of +0.26%. Regarding short-term risk, MTBCP is less volatile compared to GEHCV. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, PMCUF has a market cap of 16.10B. Regarding current trading prices, MTBCP is priced at $26.91, while PMCUF trades at $154.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas PMCUF's P/E ratio is 256.92. In terms of profitability, MTBCP's ROE is +0.17%, compared to PMCUF's ROE of +0.48%. Regarding short-term risk, MTBCP is less volatile compared to PMCUF. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, DOCS has a market cap of 11.10B. Regarding current trading prices, MTBCP is priced at $26.91, while DOCS trades at $59.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas DOCS's P/E ratio is 59.18. In terms of profitability, MTBCP's ROE is +0.17%, compared to DOCS's ROE of +0.21%. Regarding short-term risk, MTBCP is less volatile compared to DOCS. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, SGFY has a market cap of 8.93B. Regarding current trading prices, MTBCP is priced at $26.91, while SGFY trades at $30.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas SGFY's P/E ratio is 70.91. In terms of profitability, MTBCP's ROE is +0.17%, compared to SGFY's ROE of -0.15%. Regarding short-term risk, MTBCP is more volatile compared to SGFY. This indicates potentially higher risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, MTHRY has a market cap of 8.84B. Regarding current trading prices, MTBCP is priced at $26.91, while MTHRY trades at $6.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas MTHRY's P/E ratio is 31.00. In terms of profitability, MTBCP's ROE is +0.17%, compared to MTHRY's ROE of +0.09%. Regarding short-term risk, MTBCP is more volatile compared to MTHRY. This indicates potentially higher risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, MTHRF has a market cap of 8.79B. Regarding current trading prices, MTBCP is priced at $26.91, while MTHRF trades at $12.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas MTHRF's P/E ratio is 31.59. In terms of profitability, MTBCP's ROE is +0.17%, compared to MTHRF's ROE of +0.09%. Regarding short-term risk, MTBCP is more volatile compared to MTHRF. This indicates potentially higher risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, HQY has a market cap of 7.82B. Regarding current trading prices, MTBCP is priced at $26.91, while HQY trades at $90.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas HQY's P/E ratio is 82.94. In terms of profitability, MTBCP's ROE is +0.17%, compared to HQY's ROE of +0.05%. Regarding short-term risk, MTBCP is less volatile compared to HQY. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, RCM has a market cap of 6.04B. Regarding current trading prices, MTBCP is priced at $26.91, while RCM trades at $14.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas RCM's P/E ratio is -102.21. In terms of profitability, MTBCP's ROE is +0.17%, compared to RCM's ROE of -0.02%. Regarding short-term risk, MTBCP is more volatile compared to RCM. This indicates potentially higher risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, BTSG has a market cap of 3.98B. Regarding current trading prices, MTBCP is priced at $26.91, while BTSG trades at $22.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas BTSG's P/E ratio is 84.52. In terms of profitability, MTBCP's ROE is +0.17%, compared to BTSG's ROE of +0.03%. Regarding short-term risk, MTBCP is less volatile compared to BTSG. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, BTSGU has a market cap of 3.97B. Regarding current trading prices, MTBCP is priced at $26.91, while BTSGU trades at $80.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas BTSGU's P/E ratio is N/A. In terms of profitability, MTBCP's ROE is +0.17%, compared to BTSGU's ROE of +0.03%. Regarding short-term risk, MTBCP is more volatile compared to BTSGU. This indicates potentially higher risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, ONEM has a market cap of 3.40B. Regarding current trading prices, MTBCP is priced at $26.91, while ONEM trades at $16.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas ONEM's P/E ratio is -7.77. In terms of profitability, MTBCP's ROE is +0.17%, compared to ONEM's ROE of -0.24%. Regarding short-term risk, MTBCP is less volatile compared to ONEM. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, PRVA has a market cap of 3.04B. Regarding current trading prices, MTBCP is priced at $26.91, while PRVA trades at $25.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas PRVA's P/E ratio is 227.45. In terms of profitability, MTBCP's ROE is +0.17%, compared to PRVA's ROE of +0.00%. Regarding short-term risk, MTBCP is less volatile compared to PRVA. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, PINC has a market cap of 2.11B. Regarding current trading prices, MTBCP is priced at $26.91, while PINC trades at $23.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas PINC's P/E ratio is 22.62. In terms of profitability, MTBCP's ROE is +0.17%, compared to PINC's ROE of -0.00%. Regarding short-term risk, MTBCP is less volatile compared to PINC. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, PANHF has a market cap of 2.08B. Regarding current trading prices, MTBCP is priced at $26.91, while PANHF trades at $0.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas PANHF's P/E ratio is 96.20. In terms of profitability, MTBCP's ROE is +0.17%, compared to PANHF's ROE of -0.00%. Regarding short-term risk, MTBCP is less volatile compared to PANHF. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, CERT has a market cap of 1.94B. Regarding current trading prices, MTBCP is priced at $26.91, while CERT trades at $11.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas CERT's P/E ratio is -599.00. In terms of profitability, MTBCP's ROE is +0.17%, compared to CERT's ROE of -0.00%. Regarding short-term risk, MTBCP is less volatile compared to CERT. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, PGNY has a market cap of 1.82B. Regarding current trading prices, MTBCP is priced at $26.91, while PGNY trades at $21.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas PGNY's P/E ratio is 37.18. In terms of profitability, MTBCP's ROE is +0.17%, compared to PGNY's ROE of +0.12%. Regarding short-term risk, MTBCP is less volatile compared to PGNY. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, SDGR has a market cap of 1.76B. Regarding current trading prices, MTBCP is priced at $26.91, while SDGR trades at $23.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas SDGR's P/E ratio is -9.30. In terms of profitability, MTBCP's ROE is +0.17%, compared to SDGR's ROE of -0.40%. Regarding short-term risk, MTBCP is less volatile compared to SDGR. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, WGS has a market cap of 1.69B. Regarding current trading prices, MTBCP is priced at $26.91, while WGS trades at $59.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas WGS's P/E ratio is -42.55. In terms of profitability, MTBCP's ROE is +0.17%, compared to WGS's ROE of -0.17%. Regarding short-term risk, MTBCP is less volatile compared to WGS. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, NXGN has a market cap of 1.61B. Regarding current trading prices, MTBCP is priced at $26.91, while NXGN trades at $23.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas NXGN's P/E ratio is -266.00. In terms of profitability, MTBCP's ROE is +0.17%, compared to NXGN's ROE of +0.03%. Regarding short-term risk, MTBCP is more volatile compared to NXGN. This indicates potentially higher risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, GDRX has a market cap of 1.54B. Regarding current trading prices, MTBCP is priced at $26.91, while GDRX trades at $4.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas GDRX's P/E ratio is 108.00. In terms of profitability, MTBCP's ROE is +0.17%, compared to GDRX's ROE of +0.04%. Regarding short-term risk, MTBCP is less volatile compared to GDRX. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, PHR has a market cap of 1.51B. Regarding current trading prices, MTBCP is priced at $26.91, while PHR trades at $25.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas PHR's P/E ratio is -25.11. In terms of profitability, MTBCP's ROE is +0.17%, compared to PHR's ROE of -0.23%. Regarding short-term risk, MTBCP is less volatile compared to PHR. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, AGTI has a market cap of 1.37B. Regarding current trading prices, MTBCP is priced at $26.91, while AGTI trades at $10.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas AGTI's P/E ratio is -71.79. In terms of profitability, MTBCP's ROE is +0.17%, compared to AGTI's ROE of -0.03%. Regarding short-term risk, MTBCP is more volatile compared to AGTI. This indicates potentially higher risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, CMPUY has a market cap of 1.27B. Regarding current trading prices, MTBCP is priced at $26.91, while CMPUY trades at $24.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas CMPUY's P/E ratio is 41.74. In terms of profitability, MTBCP's ROE is +0.17%, compared to CMPUY's ROE of +0.04%. Regarding short-term risk, MTBCP is less volatile compared to CMPUY. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, TDOC has a market cap of 1.25B. Regarding current trading prices, MTBCP is priced at $26.91, while TDOC trades at $7.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas TDOC's P/E ratio is -1.20. In terms of profitability, MTBCP's ROE is +0.17%, compared to TDOC's ROE of -0.68%. Regarding short-term risk, MTBCP is less volatile compared to TDOC. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, PIAHY has a market cap of 1.24B. Regarding current trading prices, MTBCP is priced at $26.91, while PIAHY trades at $2.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas PIAHY's P/E ratio is 114.50. In terms of profitability, MTBCP's ROE is +0.17%, compared to PIAHY's ROE of -0.00%. Regarding short-term risk, MTBCP is less volatile compared to PIAHY. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, CMPVF has a market cap of 1.23B. Regarding current trading prices, MTBCP is priced at $26.91, while CMPVF trades at $23.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas CMPVF's P/E ratio is 40.43. In terms of profitability, MTBCP's ROE is +0.17%, compared to CMPVF's ROE of +0.04%. Regarding short-term risk, MTBCP is more volatile compared to CMPVF. This indicates potentially higher risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, OMCL has a market cap of 1.21B. Regarding current trading prices, MTBCP is priced at $26.91, while OMCL trades at $25.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas OMCL's P/E ratio is 56.04. In terms of profitability, MTBCP's ROE is +0.17%, compared to OMCL's ROE of +0.01%. Regarding short-term risk, MTBCP is less volatile compared to OMCL. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, TXG has a market cap of 1.08B. Regarding current trading prices, MTBCP is priced at $26.91, while TXG trades at $8.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas TXG's P/E ratio is -5.77. In terms of profitability, MTBCP's ROE is +0.17%, compared to TXG's ROE of -0.25%. Regarding short-term risk, MTBCP is less volatile compared to TXG. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, EVH has a market cap of 1.06B. Regarding current trading prices, MTBCP is priced at $26.91, while EVH trades at $9.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas EVH's P/E ratio is -11.05. In terms of profitability, MTBCP's ROE is +0.17%, compared to EVH's ROE of -0.06%. Regarding short-term risk, MTBCP is less volatile compared to EVH. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, HSTM has a market cap of 849.82M. Regarding current trading prices, MTBCP is priced at $26.91, while HSTM trades at $27.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas HSTM's P/E ratio is 44.19. In terms of profitability, MTBCP's ROE is +0.17%, compared to HSTM's ROE of +0.05%. Regarding short-term risk, MTBCP is less volatile compared to HSTM. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, CRWRF has a market cap of 849.22M. Regarding current trading prices, MTBCP is priced at $26.91, while CRWRF trades at $24.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas CRWRF's P/E ratio is 57.74. In terms of profitability, MTBCP's ROE is +0.17%, compared to CRWRF's ROE of +0.04%. Regarding short-term risk, MTBCP is more volatile compared to CRWRF. This indicates potentially higher risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, RSLBF has a market cap of 816.36M. Regarding current trading prices, MTBCP is priced at $26.91, while RSLBF trades at $22.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas RSLBF's P/E ratio is 36.89. In terms of profitability, MTBCP's ROE is +0.17%, compared to RSLBF's ROE of +0.25%. Regarding short-term risk, MTBCP is less volatile compared to RSLBF. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, SMSZF has a market cap of 727.28M. Regarding current trading prices, MTBCP is priced at $26.91, while SMSZF trades at $8.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas SMSZF's P/E ratio is 17.47. In terms of profitability, MTBCP's ROE is +0.17%, compared to SMSZF's ROE of +0.20%. Regarding short-term risk, MTBCP is more volatile compared to SMSZF. This indicates potentially higher risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, NUTX has a market cap of 667.45M. Regarding current trading prices, MTBCP is priced at $26.91, while NUTX trades at $120.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas NUTX's P/E ratio is 12.43. In terms of profitability, MTBCP's ROE is +0.17%, compared to NUTX's ROE of +0.63%. Regarding short-term risk, MTBCP is less volatile compared to NUTX. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, SLP has a market cap of 647.57M. Regarding current trading prices, MTBCP is priced at $26.91, while SLP trades at $32.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas SLP's P/E ratio is 89.44. In terms of profitability, MTBCP's ROE is +0.17%, compared to SLP's ROE of +0.04%. Regarding short-term risk, MTBCP is less volatile compared to SLP. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, SUSRF has a market cap of 643.95M. Regarding current trading prices, MTBCP is priced at $26.91, while SUSRF trades at $12.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas SUSRF's P/E ratio is 46.74. In terms of profitability, MTBCP's ROE is +0.17%, compared to SUSRF's ROE of +0.03%. Regarding short-term risk, MTBCP is less volatile compared to SUSRF. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, MPLN-WT has a market cap of 625.23M. Regarding current trading prices, MTBCP is priced at $26.91, while MPLN-WT trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas MPLN-WT's P/E ratio is N/A. In terms of profitability, MTBCP's ROE is +0.17%, compared to MPLN-WT's ROE of -3.19%. Regarding short-term risk, MTBCP is less volatile compared to MPLN-WT. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, ACCD has a market cap of 575.59M. Regarding current trading prices, MTBCP is priced at $26.91, while ACCD trades at $7.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas ACCD's P/E ratio is -3.08. In terms of profitability, MTBCP's ROE is +0.17%, compared to ACCD's ROE of -0.45%. Regarding short-term risk, MTBCP is more volatile compared to ACCD. This indicates potentially higher risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, CCLDP has a market cap of 566.58M. Regarding current trading prices, MTBCP is priced at $26.91, while CCLDP trades at $19.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas CCLDP's P/E ratio is N/A. In terms of profitability, MTBCP's ROE is +0.17%, compared to CCLDP's ROE of +0.17%. Regarding short-term risk, MTBCP is more volatile compared to CCLDP. This indicates potentially higher risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, SHCR has a market cap of 531.78M. Regarding current trading prices, MTBCP is priced at $26.91, while SHCR trades at $1.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas SHCR's P/E ratio is -3.76. In terms of profitability, MTBCP's ROE is +0.17%, compared to SHCR's ROE of -0.29%. Regarding short-term risk, MTBCP is more volatile compared to SHCR. This indicates potentially higher risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, VHIBF has a market cap of 457.31M. Regarding current trading prices, MTBCP is priced at $26.91, while VHIBF trades at $8.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas VHIBF's P/E ratio is 211.75. In terms of profitability, MTBCP's ROE is +0.17%, compared to VHIBF's ROE of +0.02%. Regarding short-term risk, MTBCP is less volatile compared to VHIBF. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, KSIOF has a market cap of 439.89M. Regarding current trading prices, MTBCP is priced at $26.91, while KSIOF trades at $4.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas KSIOF's P/E ratio is -77.67. In terms of profitability, MTBCP's ROE is +0.17%, compared to KSIOF's ROE of -0.20%. Regarding short-term risk, MTBCP is less volatile compared to KSIOF. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, DH has a market cap of 398.38M. Regarding current trading prices, MTBCP is priced at $26.91, while DH trades at $3.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas DH's P/E ratio is -1.04. In terms of profitability, MTBCP's ROE is +0.17%, compared to DH's ROE of -0.67%. Regarding short-term risk, MTBCP is less volatile compared to DH. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, SLGCW has a market cap of 396.23M. Regarding current trading prices, MTBCP is priced at $26.91, while SLGCW trades at $0.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas SLGCW's P/E ratio is -0.16. In terms of profitability, MTBCP's ROE is +0.17%, compared to SLGCW's ROE of -0.09%. Regarding short-term risk, MTBCP is less volatile compared to SLGCW. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, SLGC has a market cap of 396.23M. Regarding current trading prices, MTBCP is priced at $26.91, while SLGC trades at $2.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas SLGC's P/E ratio is -3.04. In terms of profitability, MTBCP's ROE is +0.17%, compared to SLGC's ROE of -0.09%. Regarding short-term risk, MTBCP is less volatile compared to SLGC. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, MPLN has a market cap of 374.98M. Regarding current trading prices, MTBCP is priced at $26.91, while MPLN trades at $23.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas MPLN's P/E ratio is -0.23. In terms of profitability, MTBCP's ROE is +0.17%, compared to MPLN's ROE of -3.19%. Regarding short-term risk, MTBCP is less volatile compared to MPLN. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, TBRG has a market cap of 370.89M. Regarding current trading prices, MTBCP is priced at $26.91, while TBRG trades at $24.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas TBRG's P/E ratio is -17.98. In terms of profitability, MTBCP's ROE is +0.17%, compared to TBRG's ROE of -0.11%. Regarding short-term risk, MTBCP is less volatile compared to TBRG. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, CTEV has a market cap of 365.13M. Regarding current trading prices, MTBCP is priced at $26.91, while CTEV trades at $21.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas CTEV's P/E ratio is -0.21. In terms of profitability, MTBCP's ROE is +0.17%, compared to CTEV's ROE of N/A. Regarding short-term risk, MTBCP is less volatile compared to CTEV. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, SPOK has a market cap of 338.62M. Regarding current trading prices, MTBCP is priced at $26.91, while SPOK trades at $16.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas SPOK's P/E ratio is 21.38. In terms of profitability, MTBCP's ROE is +0.17%, compared to SPOK's ROE of +0.10%. Regarding short-term risk, MTBCP is more volatile compared to SPOK. This indicates potentially higher risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, NRC has a market cap of 295.98M. Regarding current trading prices, MTBCP is priced at $26.91, while NRC trades at $12.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas NRC's P/E ratio is 12.74. In terms of profitability, MTBCP's ROE is +0.17%, compared to NRC's ROE of +0.71%. Regarding short-term risk, MTBCP is less volatile compared to NRC. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, HCAT has a market cap of 287.40M. Regarding current trading prices, MTBCP is priced at $26.91, while HCAT trades at $4.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas HCAT's P/E ratio is -3.59. In terms of profitability, MTBCP's ROE is +0.17%, compared to HCAT's ROE of -0.19%. Regarding short-term risk, MTBCP is less volatile compared to HCAT. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, TRHC has a market cap of 284.03M. Regarding current trading prices, MTBCP is priced at $26.91, while TRHC trades at $10.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas TRHC's P/E ratio is -4.27. In terms of profitability, MTBCP's ROE is +0.17%, compared to TRHC's ROE of +121.31%. Regarding short-term risk, MTBCP is more volatile compared to TRHC. This indicates potentially higher risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, SMDCF has a market cap of 280.87M. Regarding current trading prices, MTBCP is priced at $26.91, while SMDCF trades at $17.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas SMDCF's P/E ratio is -17.32. In terms of profitability, MTBCP's ROE is +0.17%, compared to SMDCF's ROE of N/A. Regarding short-term risk, MTBCP is more volatile compared to SMDCF. This indicates potentially higher risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, DLHTF has a market cap of 254.80M. Regarding current trading prices, MTBCP is priced at $26.91, while DLHTF trades at $3.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas DLHTF's P/E ratio is -17.24. In terms of profitability, MTBCP's ROE is +0.17%, compared to DLHTF's ROE of -0.24%. Regarding short-term risk, MTBCP is more volatile compared to DLHTF. This indicates potentially higher risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, SMFR has a market cap of 246.37M. Regarding current trading prices, MTBCP is priced at $26.91, while SMFR trades at $0.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas SMFR's P/E ratio is N/A. In terms of profitability, MTBCP's ROE is +0.17%, compared to SMFR's ROE of -0.17%. Regarding short-term risk, MTBCP is less volatile compared to SMFR. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, SOPH has a market cap of 195.75M. Regarding current trading prices, MTBCP is priced at $26.91, while SOPH trades at $2.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas SOPH's P/E ratio is -3.08. In terms of profitability, MTBCP's ROE is +0.17%, compared to SOPH's ROE of -0.54%. Regarding short-term risk, MTBCP is less volatile compared to SOPH. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, VPAHF has a market cap of 188.24M. Regarding current trading prices, MTBCP is priced at $26.91, while VPAHF trades at $0.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas VPAHF's P/E ratio is -37.00. In terms of profitability, MTBCP's ROE is +0.17%, compared to VPAHF's ROE of -0.18%. Regarding short-term risk, MTBCP is more volatile compared to VPAHF. This indicates potentially higher risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, OPRX has a market cap of 184.75M. Regarding current trading prices, MTBCP is priced at $26.91, while OPRX trades at $9.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas OPRX's P/E ratio is -9.08. In terms of profitability, MTBCP's ROE is +0.17%, compared to OPRX's ROE of -0.17%. Regarding short-term risk, MTBCP is less volatile compared to OPRX. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, COGZF has a market cap of 150.20M. Regarding current trading prices, MTBCP is priced at $26.91, while COGZF trades at $0.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas COGZF's P/E ratio is 22.00. In terms of profitability, MTBCP's ROE is +0.17%, compared to COGZF's ROE of +0.17%. Regarding short-term risk, MTBCP is less volatile compared to COGZF. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, EUDA has a market cap of 144.17M. Regarding current trading prices, MTBCP is priced at $26.91, while EUDA trades at $3.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas EUDA's P/E ratio is -7.19. In terms of profitability, MTBCP's ROE is +0.17%, compared to EUDA's ROE of +3.05%. Regarding short-term risk, MTBCP is less volatile compared to EUDA. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, ONVVF has a market cap of 141.26M. Regarding current trading prices, MTBCP is priced at $26.91, while ONVVF trades at $0.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas ONVVF's P/E ratio is -8.00. In terms of profitability, MTBCP's ROE is +0.17%, compared to ONVVF's ROE of -0.97%. Regarding short-term risk, MTBCP is less volatile compared to ONVVF. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, CPSI has a market cap of 133.71M. Regarding current trading prices, MTBCP is priced at $26.91, while CPSI trades at $9.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas CPSI's P/E ratio is -183.80. In terms of profitability, MTBCP's ROE is +0.17%, compared to CPSI's ROE of -0.03%. Regarding short-term risk, MTBCP is less volatile compared to CPSI. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, ACMLF has a market cap of 130.74M. Regarding current trading prices, MTBCP is priced at $26.91, while ACMLF trades at $3.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas ACMLF's P/E ratio is 7.14. In terms of profitability, MTBCP's ROE is +0.17%, compared to ACMLF's ROE of +0.21%. Regarding short-term risk, MTBCP is less volatile compared to ACMLF. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, AUGX has a market cap of 115.91M. Regarding current trading prices, MTBCP is priced at $26.91, while AUGX trades at $2.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas AUGX's P/E ratio is -4.99. In terms of profitability, MTBCP's ROE is +0.17%, compared to AUGX's ROE of -1.82%. Regarding short-term risk, MTBCP is more volatile compared to AUGX. This indicates potentially higher risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, SY has a market cap of 109.96M. Regarding current trading prices, MTBCP is priced at $26.91, while SY trades at $0.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas SY's P/E ratio is -1.06. In terms of profitability, MTBCP's ROE is +0.17%, compared to SY's ROE of -0.26%. Regarding short-term risk, MTBCP is less volatile compared to SY. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, AMWL has a market cap of 108.77M. Regarding current trading prices, MTBCP is priced at $26.91, while AMWL trades at $6.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas AMWL's P/E ratio is -0.68. In terms of profitability, MTBCP's ROE is +0.17%, compared to AMWL's ROE of -0.48%. Regarding short-term risk, MTBCP is less volatile compared to AMWL. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, CSAMF has a market cap of 98.80M. Regarding current trading prices, MTBCP is priced at $26.91, while CSAMF trades at $4.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas CSAMF's P/E ratio is -9.64. In terms of profitability, MTBCP's ROE is +0.17%, compared to CSAMF's ROE of -1.58%. Regarding short-term risk, MTBCP is more volatile compared to CSAMF. This indicates potentially higher risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, CCLD has a market cap of 80.62M. Regarding current trading prices, MTBCP is priced at $26.91, while CCLD trades at $1.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas CCLD's P/E ratio is -6.80. In terms of profitability, MTBCP's ROE is +0.17%, compared to CCLD's ROE of +0.17%. Regarding short-term risk, MTBCP is less volatile compared to CCLD. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, CCLDO has a market cap of 77.59M. Regarding current trading prices, MTBCP is priced at $26.91, while CCLDO trades at $19.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas CCLDO's P/E ratio is N/A. In terms of profitability, MTBCP's ROE is +0.17%, compared to CCLDO's ROE of +0.17%. Regarding short-term risk, MTBCP is less volatile compared to CCLDO. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, MDPEF has a market cap of 61.32M. Regarding current trading prices, MTBCP is priced at $26.91, while MDPEF trades at $2.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas MDPEF's P/E ratio is 6.00. In terms of profitability, MTBCP's ROE is +0.17%, compared to MDPEF's ROE of N/A. Regarding short-term risk, MTBCP is less volatile compared to MDPEF. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, BEAT has a market cap of 59.69M. Regarding current trading prices, MTBCP is priced at $26.91, while BEAT trades at $1.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas BEAT's P/E ratio is -2.42. In terms of profitability, MTBCP's ROE is +0.17%, compared to BEAT's ROE of -2.81%. Regarding short-term risk, MTBCP is less volatile compared to BEAT. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, FORA has a market cap of 58.53M. Regarding current trading prices, MTBCP is priced at $26.91, while FORA trades at $1.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas FORA's P/E ratio is -15.64. In terms of profitability, MTBCP's ROE is +0.17%, compared to FORA's ROE of -0.14%. Regarding short-term risk, MTBCP is less volatile compared to FORA. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, BEATW has a market cap of 56.82M. Regarding current trading prices, MTBCP is priced at $26.91, while BEATW trades at $0.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas BEATW's P/E ratio is -1.05. In terms of profitability, MTBCP's ROE is +0.17%, compared to BEATW's ROE of -2.81%. Regarding short-term risk, MTBCP is less volatile compared to BEATW. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, HITC has a market cap of 52.84M. Regarding current trading prices, MTBCP is priced at $26.91, while HITC trades at $0.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas HITC's P/E ratio is -14.75. In terms of profitability, MTBCP's ROE is +0.17%, compared to HITC's ROE of -1.29%. Regarding short-term risk, MTBCP is less volatile compared to HITC. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, SHLT has a market cap of 41.56M. Regarding current trading prices, MTBCP is priced at $26.91, while SHLT trades at $2.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas SHLT's P/E ratio is -4.68. In terms of profitability, MTBCP's ROE is +0.17%, compared to SHLT's ROE of -0.09%. Regarding short-term risk, MTBCP is less volatile compared to SHLT. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, SNCE has a market cap of 34.66M. Regarding current trading prices, MTBCP is priced at $26.91, while SNCE trades at $5.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas SNCE's P/E ratio is -0.27. In terms of profitability, MTBCP's ROE is +0.17%, compared to SNCE's ROE of -0.59%. Regarding short-term risk, MTBCP is more volatile compared to SNCE. This indicates potentially higher risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, AKLI has a market cap of 34.10M. Regarding current trading prices, MTBCP is priced at $26.91, while AKLI trades at $0.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas AKLI's P/E ratio is -0.71. In terms of profitability, MTBCP's ROE is +0.17%, compared to AKLI's ROE of -0.74%. Regarding short-term risk, MTBCP is more volatile compared to AKLI. This indicates potentially higher risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, SHCRW has a market cap of 32.55M. Regarding current trading prices, MTBCP is priced at $26.91, while SHCRW trades at $0.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas SHCRW's P/E ratio is -0.00. In terms of profitability, MTBCP's ROE is +0.17%, compared to SHCRW's ROE of -0.29%. Regarding short-term risk, MTBCP is less volatile compared to SHCRW. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, RQHTF has a market cap of 30.03M. Regarding current trading prices, MTBCP is priced at $26.91, while RQHTF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas RQHTF's P/E ratio is N/A. In terms of profitability, MTBCP's ROE is +0.17%, compared to RQHTF's ROE of -2.22%. Regarding short-term risk, MTBCP is less volatile compared to RQHTF. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, VASO has a market cap of 23.54M. Regarding current trading prices, MTBCP is priced at $26.91, while VASO trades at $0.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas VASO's P/E ratio is 13.40. In terms of profitability, MTBCP's ROE is +0.17%, compared to VASO's ROE of +0.04%. Regarding short-term risk, MTBCP is less volatile compared to VASO. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, RNLX has a market cap of 22.55M. Regarding current trading prices, MTBCP is priced at $26.91, while RNLX trades at $0.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas RNLX's P/E ratio is -0.33. In terms of profitability, MTBCP's ROE is +0.17%, compared to RNLX's ROE of +4.71%. Regarding short-term risk, MTBCP is less volatile compared to RNLX. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, RTNXF has a market cap of 22.55M. Regarding current trading prices, MTBCP is priced at $26.91, while RTNXF trades at $0.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas RTNXF's P/E ratio is -0.33. In terms of profitability, MTBCP's ROE is +0.17%, compared to RTNXF's ROE of +4.71%. Regarding short-term risk, MTBCP is less volatile compared to RTNXF. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, LIFW has a market cap of 22.36M. Regarding current trading prices, MTBCP is priced at $26.91, while LIFW trades at $3.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas LIFW's P/E ratio is -0.02. In terms of profitability, MTBCP's ROE is +0.17%, compared to LIFW's ROE of -0.35%. Regarding short-term risk, MTBCP is more volatile compared to LIFW. This indicates potentially higher risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, HDSLF has a market cap of 21.13M. Regarding current trading prices, MTBCP is priced at $26.91, while HDSLF trades at $0.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas HDSLF's P/E ratio is -3.22. In terms of profitability, MTBCP's ROE is +0.17%, compared to HDSLF's ROE of -1.31%. Regarding short-term risk, MTBCP is more volatile compared to HDSLF. This indicates potentially higher risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, MSPR has a market cap of 19.07M. Regarding current trading prices, MTBCP is priced at $26.91, while MSPR trades at $1.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas MSPR's P/E ratio is -0.01. In terms of profitability, MTBCP's ROE is +0.17%, compared to MSPR's ROE of -0.35%. Regarding short-term risk, MTBCP is less volatile compared to MSPR. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, VSEE has a market cap of 18.48M. Regarding current trading prices, MTBCP is priced at $26.91, while VSEE trades at $1.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas VSEE's P/E ratio is -14.75. In terms of profitability, MTBCP's ROE is +0.17%, compared to VSEE's ROE of -6.10%. Regarding short-term risk, MTBCP is less volatile compared to VSEE. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, THKKF has a market cap of 17.81M. Regarding current trading prices, MTBCP is priced at $26.91, while THKKF trades at $0.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas THKKF's P/E ratio is -1.51. In terms of profitability, MTBCP's ROE is +0.17%, compared to THKKF's ROE of -0.61%. Regarding short-term risk, MTBCP is more volatile compared to THKKF. This indicates potentially higher risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, VSEEW has a market cap of 17.74M. Regarding current trading prices, MTBCP is priced at $26.91, while VSEEW trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas VSEEW's P/E ratio is N/A. In terms of profitability, MTBCP's ROE is +0.17%, compared to VSEEW's ROE of -6.10%. Regarding short-term risk, MTBCP is less volatile compared to VSEEW. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, DGNOF has a market cap of 17.65M. Regarding current trading prices, MTBCP is priced at $26.91, while DGNOF trades at $0.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas DGNOF's P/E ratio is -5.77. In terms of profitability, MTBCP's ROE is +0.17%, compared to DGNOF's ROE of +2.18%. Regarding short-term risk, MTBCP is less volatile compared to DGNOF. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, BFRG has a market cap of 16.57M. Regarding current trading prices, MTBCP is priced at $26.91, while BFRG trades at $1.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas BFRG's P/E ratio is -2.07. In terms of profitability, MTBCP's ROE is +0.17%, compared to BFRG's ROE of -1.33%. Regarding short-term risk, MTBCP is less volatile compared to BFRG. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, UDOCF has a market cap of 16.03M. Regarding current trading prices, MTBCP is priced at $26.91, while UDOCF trades at $0.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas UDOCF's P/E ratio is -3.50. In terms of profitability, MTBCP's ROE is +0.17%, compared to UDOCF's ROE of +6.57%. Regarding short-term risk, MTBCP is less volatile compared to UDOCF. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, TREIF has a market cap of 15.72M. Regarding current trading prices, MTBCP is priced at $26.91, while TREIF trades at $0.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas TREIF's P/E ratio is -2.26. In terms of profitability, MTBCP's ROE is +0.17%, compared to TREIF's ROE of -11.21%. Regarding short-term risk, MTBCP is less volatile compared to TREIF. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, MNNDF has a market cap of 14.25M. Regarding current trading prices, MTBCP is priced at $26.91, while MNNDF trades at $0.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas MNNDF's P/E ratio is -1.48. In terms of profitability, MTBCP's ROE is +0.17%, compared to MNNDF's ROE of N/A. Regarding short-term risk, MTBCP is less volatile compared to MNNDF. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, BBLN has a market cap of 14.10M. Regarding current trading prices, MTBCP is priced at $26.91, while BBLN trades at $0.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas BBLN's P/E ratio is -0.04. In terms of profitability, MTBCP's ROE is +0.17%, compared to BBLN's ROE of +4.89%. Regarding short-term risk, MTBCP is less volatile compared to BBLN. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, INOV has a market cap of 13.89M. Regarding current trading prices, MTBCP is priced at $26.91, while INOV trades at $31.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas INOV's P/E ratio is 16.35. In terms of profitability, MTBCP's ROE is +0.17%, compared to INOV's ROE of +0.03%. Regarding short-term risk, MTBCP is more volatile compared to INOV. This indicates potentially higher risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, AIMLF has a market cap of 13.00M. Regarding current trading prices, MTBCP is priced at $26.91, while AIMLF trades at $0.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas AIMLF's P/E ratio is -1.87. In terms of profitability, MTBCP's ROE is +0.17%, compared to AIMLF's ROE of -11.81%. Regarding short-term risk, MTBCP is more volatile compared to AIMLF. This indicates potentially higher risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, ONMD has a market cap of 12.61M. Regarding current trading prices, MTBCP is priced at $26.91, while ONMD trades at $0.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas ONMD's P/E ratio is -1.14. In terms of profitability, MTBCP's ROE is +0.17%, compared to ONMD's ROE of +0.62%. Regarding short-term risk, MTBCP is less volatile compared to ONMD. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, STRM has a market cap of 11.69M. Regarding current trading prices, MTBCP is priced at $26.91, while STRM trades at $2.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas STRM's P/E ratio is -1.07. In terms of profitability, MTBCP's ROE is +0.17%, compared to STRM's ROE of -0.80%. Regarding short-term risk, MTBCP is less volatile compared to STRM. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, CRVW has a market cap of 11.68M. Regarding current trading prices, MTBCP is priced at $26.91, while CRVW trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas CRVW's P/E ratio is -2.00. In terms of profitability, MTBCP's ROE is +0.17%, compared to CRVW's ROE of +0.12%. Regarding short-term risk, MTBCP is less volatile compared to CRVW. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, SCNX has a market cap of 11.51M. Regarding current trading prices, MTBCP is priced at $26.91, while SCNX trades at $0.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas SCNX's P/E ratio is -0.17. In terms of profitability, MTBCP's ROE is +0.17%, compared to SCNX's ROE of +0.19%. Regarding short-term risk, MTBCP is less volatile compared to SCNX. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, PBSV has a market cap of 11.46M. Regarding current trading prices, MTBCP is priced at $26.91, while PBSV trades at $0.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas PBSV's P/E ratio is -25.00. In terms of profitability, MTBCP's ROE is +0.17%, compared to PBSV's ROE of -0.00%. Regarding short-term risk, MTBCP is more volatile compared to PBSV. This indicates potentially higher risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, MGRX has a market cap of 10.97M. Regarding current trading prices, MTBCP is priced at $26.91, while MGRX trades at $1.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas MGRX's P/E ratio is -0.36. In terms of profitability, MTBCP's ROE is +0.17%, compared to MGRX's ROE of -0.87%. Regarding short-term risk, MTBCP is less volatile compared to MGRX. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, ETAO has a market cap of 9.78M. Regarding current trading prices, MTBCP is priced at $26.91, while ETAO trades at $1.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas ETAO's P/E ratio is -0.01. In terms of profitability, MTBCP's ROE is +0.17%, compared to ETAO's ROE of -13.69%. Regarding short-term risk, MTBCP is less volatile compared to ETAO. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, EMOR has a market cap of 9.66M. Regarding current trading prices, MTBCP is priced at $26.91, while EMOR trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas EMOR's P/E ratio is N/A. In terms of profitability, MTBCP's ROE is +0.17%, compared to EMOR's ROE of +0.28%. Regarding short-term risk, MTBCP is more volatile compared to EMOR. This indicates potentially higher risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, HSCHF has a market cap of 9.50M. Regarding current trading prices, MTBCP is priced at $26.91, while HSCHF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas HSCHF's P/E ratio is N/A. In terms of profitability, MTBCP's ROE is +0.17%, compared to HSCHF's ROE of +0.00%. Regarding short-term risk, MTBCP is more volatile compared to HSCHF. This indicates potentially higher risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, VYND has a market cap of 9.16M. Regarding current trading prices, MTBCP is priced at $26.91, while VYND trades at $0.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas VYND's P/E ratio is -24.99. In terms of profitability, MTBCP's ROE is +0.17%, compared to VYND's ROE of +0.38%. Regarding short-term risk, MTBCP is more volatile compared to VYND. This indicates potentially higher risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, HCTI has a market cap of 8.97M. Regarding current trading prices, MTBCP is priced at $26.91, while HCTI trades at $0.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas HCTI's P/E ratio is -0.18. In terms of profitability, MTBCP's ROE is +0.17%, compared to HCTI's ROE of +2.95%. Regarding short-term risk, MTBCP is less volatile compared to HCTI. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, HBCNF has a market cap of 8.44M. Regarding current trading prices, MTBCP is priced at $26.91, while HBCNF trades at $0.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas HBCNF's P/E ratio is -0.59. In terms of profitability, MTBCP's ROE is +0.17%, compared to HBCNF's ROE of -0.57%. Regarding short-term risk, MTBCP is less volatile compared to HBCNF. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, SPLTF has a market cap of 7.95M. Regarding current trading prices, MTBCP is priced at $26.91, while SPLTF trades at $0.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas SPLTF's P/E ratio is -2.60. In terms of profitability, MTBCP's ROE is +0.17%, compared to SPLTF's ROE of -6.63%. Regarding short-term risk, MTBCP is less volatile compared to SPLTF. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, HLTH has a market cap of 6.90M. Regarding current trading prices, MTBCP is priced at $26.91, while HLTH trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas HLTH's P/E ratio is -0.02. In terms of profitability, MTBCP's ROE is +0.17%, compared to HLTH's ROE of -1.04%. Regarding short-term risk, MTBCP is less volatile compared to HLTH. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, OTRK has a market cap of 6.86M. Regarding current trading prices, MTBCP is priced at $26.91, while OTRK trades at $1.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas OTRK's P/E ratio is -0.10. In terms of profitability, MTBCP's ROE is +0.17%, compared to OTRK's ROE of -1.76%. Regarding short-term risk, MTBCP is less volatile compared to OTRK. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, CRBKF has a market cap of 6.84M. Regarding current trading prices, MTBCP is priced at $26.91, while CRBKF trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas CRBKF's P/E ratio is -1.40. In terms of profitability, MTBCP's ROE is +0.17%, compared to CRBKF's ROE of +68.80%. Regarding short-term risk, MTBCP is more volatile compared to CRBKF. This indicates potentially higher risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, DOCRF has a market cap of 6.25M. Regarding current trading prices, MTBCP is priced at $26.91, while DOCRF trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas DOCRF's P/E ratio is -0.11. In terms of profitability, MTBCP's ROE is +0.17%, compared to DOCRF's ROE of -1.25%. Regarding short-term risk, MTBCP is more volatile compared to DOCRF. This indicates potentially higher risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, ZCMD has a market cap of 5.93M. Regarding current trading prices, MTBCP is priced at $26.91, while ZCMD trades at $1.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas ZCMD's P/E ratio is -9.50. In terms of profitability, MTBCP's ROE is +0.17%, compared to ZCMD's ROE of -0.03%. Regarding short-term risk, MTBCP is less volatile compared to ZCMD. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, MDBIF has a market cap of 5.50M. Regarding current trading prices, MTBCP is priced at $26.91, while MDBIF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas MDBIF's P/E ratio is -0.21. In terms of profitability, MTBCP's ROE is +0.17%, compared to MDBIF's ROE of -0.14%. Regarding short-term risk, MTBCP is less volatile compared to MDBIF. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, UPH has a market cap of 5.33M. Regarding current trading prices, MTBCP is priced at $26.91, while UPH trades at $0.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas UPH's P/E ratio is -0.07. In terms of profitability, MTBCP's ROE is +0.17%, compared to UPH's ROE of -0.54%. Regarding short-term risk, MTBCP is less volatile compared to UPH. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, CNONF has a market cap of 4.99M. Regarding current trading prices, MTBCP is priced at $26.91, while CNONF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas CNONF's P/E ratio is N/A. In terms of profitability, MTBCP's ROE is +0.17%, compared to CNONF's ROE of +1.60%. Regarding short-term risk, MTBCP is less volatile compared to CNONF. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, RYAHF has a market cap of 4.96M. Regarding current trading prices, MTBCP is priced at $26.91, while RYAHF trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas RYAHF's P/E ratio is 0.25. In terms of profitability, MTBCP's ROE is +0.17%, compared to RYAHF's ROE of +0.00%. Regarding short-term risk, MTBCP is more volatile compared to RYAHF. This indicates potentially higher risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, CDXFF has a market cap of 4.87M. Regarding current trading prices, MTBCP is priced at $26.91, while CDXFF trades at $0.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas CDXFF's P/E ratio is -1.20. In terms of profitability, MTBCP's ROE is +0.17%, compared to CDXFF's ROE of +0.44%. Regarding short-term risk, MTBCP is less volatile compared to CDXFF. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, IQAIF has a market cap of 4.19M. Regarding current trading prices, MTBCP is priced at $26.91, while IQAIF trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas IQAIF's P/E ratio is N/A. In terms of profitability, MTBCP's ROE is +0.17%, compared to IQAIF's ROE of -2.26%. Regarding short-term risk, MTBCP is less volatile compared to IQAIF. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, CMPD has a market cap of 4.17M. Regarding current trading prices, MTBCP is priced at $26.91, while CMPD trades at $3.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas CMPD's P/E ratio is -16.50. In terms of profitability, MTBCP's ROE is +0.17%, compared to CMPD's ROE of +0.07%. Regarding short-term risk, MTBCP is less volatile compared to CMPD. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, ACON has a market cap of 4.13M. Regarding current trading prices, MTBCP is priced at $26.91, while ACON trades at $7.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas ACON's P/E ratio is N/A. In terms of profitability, MTBCP's ROE is +0.17%, compared to ACON's ROE of -3.67%. Regarding short-term risk, MTBCP is less volatile compared to ACON. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, PEAR has a market cap of 4.09M. Regarding current trading prices, MTBCP is priced at $26.91, while PEAR trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas PEAR's P/E ratio is -0.08. In terms of profitability, MTBCP's ROE is +0.17%, compared to PEAR's ROE of -0.39%. Regarding short-term risk, MTBCP is less volatile compared to PEAR. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, PEARW has a market cap of 4.09M. Regarding current trading prices, MTBCP is priced at $26.91, while PEARW trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas PEARW's P/E ratio is -0.00. In terms of profitability, MTBCP's ROE is +0.17%, compared to PEARW's ROE of -0.39%. Regarding short-term risk, MTBCP is less volatile compared to PEARW. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, CBDS has a market cap of 3.83M. Regarding current trading prices, MTBCP is priced at $26.91, while CBDS trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas CBDS's P/E ratio is -1.34. In terms of profitability, MTBCP's ROE is +0.17%, compared to CBDS's ROE of +1.55%. Regarding short-term risk, MTBCP is less volatile compared to CBDS. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, EUDAW has a market cap of 3.72M. Regarding current trading prices, MTBCP is priced at $26.91, while EUDAW trades at $0.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas EUDAW's P/E ratio is N/A. In terms of profitability, MTBCP's ROE is +0.17%, compared to EUDAW's ROE of +3.05%. Regarding short-term risk, MTBCP is more volatile compared to EUDAW. This indicates potentially higher risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, ICCT has a market cap of 3.69M. Regarding current trading prices, MTBCP is priced at $26.91, while ICCT trades at $1.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas ICCT's P/E ratio is -0.03. In terms of profitability, MTBCP's ROE is +0.17%, compared to ICCT's ROE of -14.51%. Regarding short-term risk, MTBCP is less volatile compared to ICCT. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, MITI has a market cap of 2.99M. Regarding current trading prices, MTBCP is priced at $26.91, while MITI trades at $0.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas MITI's P/E ratio is -0.64. In terms of profitability, MTBCP's ROE is +0.17%, compared to MITI's ROE of +0.15%. Regarding short-term risk, MTBCP is more volatile compared to MITI. This indicates potentially higher risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, FOXO has a market cap of 2.73M. Regarding current trading prices, MTBCP is priced at $26.91, while FOXO trades at $0.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas FOXO's P/E ratio is -0.07. In terms of profitability, MTBCP's ROE is +0.17%, compared to FOXO's ROE of -0.01%. Regarding short-term risk, MTBCP is less volatile compared to FOXO. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, CMHSF has a market cap of 2.23M. Regarding current trading prices, MTBCP is priced at $26.91, while CMHSF trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas CMHSF's P/E ratio is 0.90. In terms of profitability, MTBCP's ROE is +0.17%, compared to CMHSF's ROE of +0.10%. Regarding short-term risk, MTBCP is more volatile compared to CMHSF. This indicates potentially higher risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, EKGGF has a market cap of 1.97M. Regarding current trading prices, MTBCP is priced at $26.91, while EKGGF trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas EKGGF's P/E ratio is N/A. In terms of profitability, MTBCP's ROE is +0.17%, compared to EKGGF's ROE of +0.45%. Regarding short-term risk, MTBCP is less volatile compared to EKGGF. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, EBYH has a market cap of 1.89M. Regarding current trading prices, MTBCP is priced at $26.91, while EBYH trades at $0.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas EBYH's P/E ratio is -5.43. In terms of profitability, MTBCP's ROE is +0.17%, compared to EBYH's ROE of -0.03%. Regarding short-term risk, MTBCP is more volatile compared to EBYH. This indicates potentially higher risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, BNVIF has a market cap of 1.68M. Regarding current trading prices, MTBCP is priced at $26.91, while BNVIF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas BNVIF's P/E ratio is N/A. In terms of profitability, MTBCP's ROE is +0.17%, compared to BNVIF's ROE of -4.34%. Regarding short-term risk, MTBCP is more volatile compared to BNVIF. This indicates potentially higher risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, CMAX has a market cap of 1.61M. Regarding current trading prices, MTBCP is priced at $26.91, while CMAX trades at $0.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas CMAX's P/E ratio is -0.00. In terms of profitability, MTBCP's ROE is +0.17%, compared to CMAX's ROE of +30.94%. Regarding short-term risk, MTBCP is less volatile compared to CMAX. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, CSOC has a market cap of 1.60M. Regarding current trading prices, MTBCP is priced at $26.91, while CSOC trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas CSOC's P/E ratio is 0.29. In terms of profitability, MTBCP's ROE is +0.17%, compared to CSOC's ROE of -2.38%. Regarding short-term risk, MTBCP is more volatile compared to CSOC. This indicates potentially higher risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, WORX has a market cap of 1.41M. Regarding current trading prices, MTBCP is priced at $26.91, while WORX trades at $0.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas WORX's P/E ratio is -0.78. In terms of profitability, MTBCP's ROE is +0.17%, compared to WORX's ROE of -0.28%. Regarding short-term risk, MTBCP is less volatile compared to WORX. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, LVCE has a market cap of 1.35M. Regarding current trading prices, MTBCP is priced at $26.91, while LVCE trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas LVCE's P/E ratio is N/A. In terms of profitability, MTBCP's ROE is +0.17%, compared to LVCE's ROE of N/A. Regarding short-term risk, MTBCP is more volatile compared to LVCE. This indicates potentially higher risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, WGSWW has a market cap of 1.30M. Regarding current trading prices, MTBCP is priced at $26.91, while WGSWW trades at $0.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas WGSWW's P/E ratio is N/A. In terms of profitability, MTBCP's ROE is +0.17%, compared to WGSWW's ROE of -0.17%. Regarding short-term risk, MTBCP is less volatile compared to WGSWW. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, LIFWZ has a market cap of 1.25M. Regarding current trading prices, MTBCP is priced at $26.91, while LIFWZ trades at $0.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas LIFWZ's P/E ratio is N/A. In terms of profitability, MTBCP's ROE is +0.17%, compared to LIFWZ's ROE of -0.35%. Regarding short-term risk, MTBCP is more volatile compared to LIFWZ. This indicates potentially higher risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, CTVEF has a market cap of 1.22M. Regarding current trading prices, MTBCP is priced at $26.91, while CTVEF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas CTVEF's P/E ratio is -0.11. In terms of profitability, MTBCP's ROE is +0.17%, compared to CTVEF's ROE of +0.08%. Regarding short-term risk, MTBCP is more volatile compared to CTVEF. This indicates potentially higher risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, EVAHF has a market cap of 1.09M. Regarding current trading prices, MTBCP is priced at $26.91, while EVAHF trades at $0.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas EVAHF's P/E ratio is -9.40. In terms of profitability, MTBCP's ROE is +0.17%, compared to EVAHF's ROE of +0.29%. Regarding short-term risk, MTBCP is less volatile compared to EVAHF. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, OTRKP has a market cap of 1.01M. Regarding current trading prices, MTBCP is priced at $26.91, while OTRKP trades at $0.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas OTRKP's P/E ratio is -0.08. In terms of profitability, MTBCP's ROE is +0.17%, compared to OTRKP's ROE of -1.76%. Regarding short-term risk, MTBCP is less volatile compared to OTRKP. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, PPJE has a market cap of 920484.00. Regarding current trading prices, MTBCP is priced at $26.91, while PPJE trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas PPJE's P/E ratio is N/A. In terms of profitability, MTBCP's ROE is +0.17%, compared to PPJE's ROE of +0.00%. Regarding short-term risk, MTBCP is more volatile compared to PPJE. This indicates potentially higher risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, MDXL has a market cap of 845013.00. Regarding current trading prices, MTBCP is priced at $26.91, while MDXL trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas MDXL's P/E ratio is -0.10. In terms of profitability, MTBCP's ROE is +0.17%, compared to MDXL's ROE of +0.90%. Regarding short-term risk, MTBCP is less volatile compared to MDXL. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, CGNSF has a market cap of 647206.00. Regarding current trading prices, MTBCP is priced at $26.91, while CGNSF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas CGNSF's P/E ratio is N/A. In terms of profitability, MTBCP's ROE is +0.17%, compared to CGNSF's ROE of +0.96%. Regarding short-term risk, MTBCP is less volatile compared to CGNSF. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, NEWUF has a market cap of 625851.00. Regarding current trading prices, MTBCP is priced at $26.91, while NEWUF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas NEWUF's P/E ratio is -0.02. In terms of profitability, MTBCP's ROE is +0.17%, compared to NEWUF's ROE of +0.67%. Regarding short-term risk, MTBCP is more volatile compared to NEWUF. This indicates potentially higher risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, ACHKF has a market cap of 522554.00. Regarding current trading prices, MTBCP is priced at $26.91, while ACHKF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas ACHKF's P/E ratio is -0.07. In terms of profitability, MTBCP's ROE is +0.17%, compared to ACHKF's ROE of +2.16%. Regarding short-term risk, MTBCP is less volatile compared to ACHKF. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, MDNWF has a market cap of 517288.00. Regarding current trading prices, MTBCP is priced at $26.91, while MDNWF trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas MDNWF's P/E ratio is -0.02. In terms of profitability, MTBCP's ROE is +0.17%, compared to MDNWF's ROE of -1.53%. Regarding short-term risk, MTBCP is less volatile compared to MDNWF. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, NDATF has a market cap of 450469.00. Regarding current trading prices, MTBCP is priced at $26.91, while NDATF trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas NDATF's P/E ratio is -0.55. In terms of profitability, MTBCP's ROE is +0.17%, compared to NDATF's ROE of -0.62%. Regarding short-term risk, MTBCP is more volatile compared to NDATF. This indicates potentially higher risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, MDRM has a market cap of 446418.00. Regarding current trading prices, MTBCP is priced at $26.91, while MDRM trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas MDRM's P/E ratio is -0.35. In terms of profitability, MTBCP's ROE is +0.17%, compared to MDRM's ROE of +0.42%. Regarding short-term risk, MTBCP is more volatile compared to MDRM. This indicates potentially higher risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, DTRK has a market cap of 327488.00. Regarding current trading prices, MTBCP is priced at $26.91, while DTRK trades at $0.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas DTRK's P/E ratio is -8.54. In terms of profitability, MTBCP's ROE is +0.17%, compared to DTRK's ROE of -9.79%. Regarding short-term risk, MTBCP is less volatile compared to DTRK. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, LFCOF has a market cap of 281984.00. Regarding current trading prices, MTBCP is priced at $26.91, while LFCOF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas LFCOF's P/E ratio is -0.04. In terms of profitability, MTBCP's ROE is +0.17%, compared to LFCOF's ROE of +8.70%. Regarding short-term risk, MTBCP is less volatile compared to LFCOF. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, NMXS has a market cap of 201522.00. Regarding current trading prices, MTBCP is priced at $26.91, while NMXS trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas NMXS's P/E ratio is -0.53. In terms of profitability, MTBCP's ROE is +0.17%, compared to NMXS's ROE of +1.59%. Regarding short-term risk, MTBCP is less volatile compared to NMXS. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, TSTTF has a market cap of 192400.00. Regarding current trading prices, MTBCP is priced at $26.91, while TSTTF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas TSTTF's P/E ratio is -0.07. In terms of profitability, MTBCP's ROE is +0.17%, compared to TSTTF's ROE of +0.33%. Regarding short-term risk, MTBCP is less volatile compared to TSTTF. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, EWLL has a market cap of 185077.00. Regarding current trading prices, MTBCP is priced at $26.91, while EWLL trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas EWLL's P/E ratio is N/A. In terms of profitability, MTBCP's ROE is +0.17%, compared to EWLL's ROE of +0.00%. Regarding short-term risk, MTBCP is less volatile compared to EWLL. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, KERN has a market cap of 162320.00. Regarding current trading prices, MTBCP is priced at $26.91, while KERN trades at $0.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas KERN's P/E ratio is -0.01. In terms of profitability, MTBCP's ROE is +0.17%, compared to KERN's ROE of +0.65%. Regarding short-term risk, MTBCP is less volatile compared to KERN. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, KERNW has a market cap of 162320.00. Regarding current trading prices, MTBCP is priced at $26.91, while KERNW trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas KERNW's P/E ratio is -0.00. In terms of profitability, MTBCP's ROE is +0.17%, compared to KERNW's ROE of +0.65%. Regarding short-term risk, MTBCP is less volatile compared to KERNW. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, ALDNF has a market cap of 160415.00. Regarding current trading prices, MTBCP is priced at $26.91, while ALDNF trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas ALDNF's P/E ratio is N/A. In terms of profitability, MTBCP's ROE is +0.17%, compared to ALDNF's ROE of +0.00%. Regarding short-term risk, MTBCP is more volatile compared to ALDNF. This indicates potentially higher risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, USPS has a market cap of 158503.00. Regarding current trading prices, MTBCP is priced at $26.91, while USPS trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas USPS's P/E ratio is -1.00. In terms of profitability, MTBCP's ROE is +0.17%, compared to USPS's ROE of N/A. Regarding short-term risk, MTBCP is less volatile compared to USPS. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, EMYSF has a market cap of 151670.00. Regarding current trading prices, MTBCP is priced at $26.91, while EMYSF trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas EMYSF's P/E ratio is N/A. In terms of profitability, MTBCP's ROE is +0.17%, compared to EMYSF's ROE of +0.00%. Regarding short-term risk, MTBCP is less volatile compared to EMYSF. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, DSOL has a market cap of 88891.00. Regarding current trading prices, MTBCP is priced at $26.91, while DSOL trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas DSOL's P/E ratio is N/A. In terms of profitability, MTBCP's ROE is +0.17%, compared to DSOL's ROE of +0.05%. Regarding short-term risk, MTBCP is more volatile compared to DSOL. This indicates potentially higher risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, NHIQ has a market cap of 82414.00. Regarding current trading prices, MTBCP is priced at $26.91, while NHIQ trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas NHIQ's P/E ratio is N/A. In terms of profitability, MTBCP's ROE is +0.17%, compared to NHIQ's ROE of +0.35%. Regarding short-term risk, MTBCP is less volatile compared to NHIQ. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, PASO has a market cap of 74059.00. Regarding current trading prices, MTBCP is priced at $26.91, while PASO trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas PASO's P/E ratio is N/A. In terms of profitability, MTBCP's ROE is +0.17%, compared to PASO's ROE of +6.20%. Regarding short-term risk, MTBCP is more volatile compared to PASO. This indicates potentially higher risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, ICCO has a market cap of 71654.00. Regarding current trading prices, MTBCP is priced at $26.91, while ICCO trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas ICCO's P/E ratio is -0.40. In terms of profitability, MTBCP's ROE is +0.17%, compared to ICCO's ROE of +0.17%. Regarding short-term risk, MTBCP is less volatile compared to ICCO. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, REFG has a market cap of 60838.00. Regarding current trading prices, MTBCP is priced at $26.91, while REFG trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas REFG's P/E ratio is -0.01. In terms of profitability, MTBCP's ROE is +0.17%, compared to REFG's ROE of +0.01%. Regarding short-term risk, MTBCP is more volatile compared to REFG. This indicates potentially higher risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, LIFWW has a market cap of 60053.00. Regarding current trading prices, MTBCP is priced at $26.91, while LIFWW trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas LIFWW's P/E ratio is N/A. In terms of profitability, MTBCP's ROE is +0.17%, compared to LIFWW's ROE of -0.35%. Regarding short-term risk, MTBCP is more volatile compared to LIFWW. This indicates potentially higher risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, MSPRZ has a market cap of 47383.00. Regarding current trading prices, MTBCP is priced at $26.91, while MSPRZ trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas MSPRZ's P/E ratio is N/A. In terms of profitability, MTBCP's ROE is +0.17%, compared to MSPRZ's ROE of -0.35%. Regarding short-term risk, MTBCP is less volatile compared to MSPRZ. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, SOFE has a market cap of 45131.00. Regarding current trading prices, MTBCP is priced at $26.91, while SOFE trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas SOFE's P/E ratio is N/A. In terms of profitability, MTBCP's ROE is +0.17%, compared to SOFE's ROE of +0.52%. Regarding short-term risk, MTBCP is less volatile compared to SOFE. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, HDVY has a market cap of 41171.00. Regarding current trading prices, MTBCP is priced at $26.91, while HDVY trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas HDVY's P/E ratio is N/A. In terms of profitability, MTBCP's ROE is +0.17%, compared to HDVY's ROE of +0.00%. Regarding short-term risk, MTBCP is more volatile compared to HDVY. This indicates potentially higher risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, IGRW has a market cap of 39815.00. Regarding current trading prices, MTBCP is priced at $26.91, while IGRW trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas IGRW's P/E ratio is -0.00. In terms of profitability, MTBCP's ROE is +0.17%, compared to IGRW's ROE of +7.88%. Regarding short-term risk, MTBCP is less volatile compared to IGRW. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, CMAXW has a market cap of 36386.00. Regarding current trading prices, MTBCP is priced at $26.91, while CMAXW trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas CMAXW's P/E ratio is N/A. In terms of profitability, MTBCP's ROE is +0.17%, compared to CMAXW's ROE of +30.94%. Regarding short-term risk, MTBCP is more volatile compared to CMAXW. This indicates potentially higher risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, WMGR has a market cap of 36250.00. Regarding current trading prices, MTBCP is priced at $26.91, while WMGR trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas WMGR's P/E ratio is N/A. In terms of profitability, MTBCP's ROE is +0.17%, compared to WMGR's ROE of +0.00%. Regarding short-term risk, MTBCP is less volatile compared to WMGR. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, SSYNF has a market cap of 33293.00. Regarding current trading prices, MTBCP is priced at $26.91, while SSYNF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas SSYNF's P/E ratio is -0.00. In terms of profitability, MTBCP's ROE is +0.17%, compared to SSYNF's ROE of N/A. Regarding short-term risk, MTBCP is more volatile compared to SSYNF. This indicates potentially higher risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, RVRC has a market cap of 31411.00. Regarding current trading prices, MTBCP is priced at $26.91, while RVRC trades at $0.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas RVRC's P/E ratio is -0.09. In terms of profitability, MTBCP's ROE is +0.17%, compared to RVRC's ROE of -0.29%. Regarding short-term risk, MTBCP is less volatile compared to RVRC. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, TTBLF has a market cap of 26744.00. Regarding current trading prices, MTBCP is priced at $26.91, while TTBLF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas TTBLF's P/E ratio is -0.00. In terms of profitability, MTBCP's ROE is +0.17%, compared to TTBLF's ROE of -1.03%. Regarding short-term risk, MTBCP is less volatile compared to TTBLF. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, ORHB has a market cap of 25558.00. Regarding current trading prices, MTBCP is priced at $26.91, while ORHB trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas ORHB's P/E ratio is -0.01. In terms of profitability, MTBCP's ROE is +0.17%, compared to ORHB's ROE of +0.33%. Regarding short-term risk, MTBCP is more volatile compared to ORHB. This indicates potentially higher risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, ACONW has a market cap of 20907.00. Regarding current trading prices, MTBCP is priced at $26.91, while ACONW trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas ACONW's P/E ratio is -0.01. In terms of profitability, MTBCP's ROE is +0.17%, compared to ACONW's ROE of -3.67%. Regarding short-term risk, MTBCP is more volatile compared to ACONW. This indicates potentially higher risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, NHEL has a market cap of 16219.00. Regarding current trading prices, MTBCP is priced at $26.91, while NHEL trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas NHEL's P/E ratio is N/A. In terms of profitability, MTBCP's ROE is +0.17%, compared to NHEL's ROE of +0.00%. Regarding short-term risk, MTBCP is more volatile compared to NHEL. This indicates potentially higher risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, FDBH has a market cap of 15022.00. Regarding current trading prices, MTBCP is priced at $26.91, while FDBH trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas FDBH's P/E ratio is N/A. In terms of profitability, MTBCP's ROE is +0.17%, compared to FDBH's ROE of +0.32%. Regarding short-term risk, MTBCP is more volatile compared to FDBH. This indicates potentially higher risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, HLTT has a market cap of 10663.00. Regarding current trading prices, MTBCP is priced at $26.91, while HLTT trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas HLTT's P/E ratio is N/A. In terms of profitability, MTBCP's ROE is +0.17%, compared to HLTT's ROE of +1789941.38%. Regarding short-term risk, MTBCP is more volatile compared to HLTT. This indicates potentially higher risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, MOSTQ has a market cap of 8517.00. Regarding current trading prices, MTBCP is priced at $26.91, while MOSTQ trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas MOSTQ's P/E ratio is N/A. In terms of profitability, MTBCP's ROE is +0.17%, compared to MOSTQ's ROE of +2.26%. Regarding short-term risk, MTBCP is more volatile compared to MOSTQ. This indicates potentially higher risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, AHGIF has a market cap of 7789.00. Regarding current trading prices, MTBCP is priced at $26.91, while AHGIF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas AHGIF's P/E ratio is N/A. In terms of profitability, MTBCP's ROE is +0.17%, compared to AHGIF's ROE of -2.79%. Regarding short-term risk, MTBCP is less volatile compared to AHGIF. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, MSPRW has a market cap of 7700.00. Regarding current trading prices, MTBCP is priced at $26.91, while MSPRW trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas MSPRW's P/E ratio is N/A. In terms of profitability, MTBCP's ROE is +0.17%, compared to MSPRW's ROE of -0.35%. Regarding short-term risk, MTBCP is less volatile compared to MSPRW. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, BBLNF has a market cap of 2561.00. Regarding current trading prices, MTBCP is priced at $26.91, while BBLNF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas BBLNF's P/E ratio is N/A. In terms of profitability, MTBCP's ROE is +0.17%, compared to BBLNF's ROE of +1.06%. Regarding short-term risk, MTBCP is more volatile compared to BBLNF. This indicates potentially higher risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, PCYS has a market cap of 1105.00. Regarding current trading prices, MTBCP is priced at $26.91, while PCYS trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas PCYS's P/E ratio is N/A. In terms of profitability, MTBCP's ROE is +0.17%, compared to PCYS's ROE of N/A. Regarding short-term risk, MTBCP is less volatile compared to PCYS. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, OLMM has a market cap of 1005.00. Regarding current trading prices, MTBCP is priced at $26.91, while OLMM trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas OLMM's P/E ratio is N/A. In terms of profitability, MTBCP's ROE is +0.17%, compared to OLMM's ROE of +0.00%. Regarding short-term risk, MTBCP is less volatile compared to OLMM. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, UTRS has a market cap of 888.00. Regarding current trading prices, MTBCP is priced at $26.91, while UTRS trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas UTRS's P/E ratio is N/A. In terms of profitability, MTBCP's ROE is +0.17%, compared to UTRS's ROE of -1.11%. Regarding short-term risk, MTBCP is more volatile compared to UTRS. This indicates potentially higher risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, ACNV has a market cap of 814.00. Regarding current trading prices, MTBCP is priced at $26.91, while ACNV trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas ACNV's P/E ratio is N/A. In terms of profitability, MTBCP's ROE is +0.17%, compared to ACNV's ROE of +0.00%. Regarding short-term risk, MTBCP is less volatile compared to ACNV. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, ETAOF has a market cap of 512.00. Regarding current trading prices, MTBCP is priced at $26.91, while ETAOF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas ETAOF's P/E ratio is N/A. In terms of profitability, MTBCP's ROE is +0.17%, compared to ETAOF's ROE of -13.69%. Regarding short-term risk, MTBCP is less volatile compared to ETAOF. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, LGBI has a market cap of 50.00. Regarding current trading prices, MTBCP is priced at $26.91, while LGBI trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas LGBI's P/E ratio is N/A. In terms of profitability, MTBCP's ROE is +0.17%, compared to LGBI's ROE of +0.00%. Regarding short-term risk, MTBCP is less volatile compared to LGBI. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, APYI has a market cap of 34.00. Regarding current trading prices, MTBCP is priced at $26.91, while APYI trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas APYI's P/E ratio is N/A. In terms of profitability, MTBCP's ROE is +0.17%, compared to APYI's ROE of -0.60%. Regarding short-term risk, MTBCP is more volatile compared to APYI. This indicates potentially higher risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, CERN comparison data is unavailable. Regarding current trading prices, MTBCP is priced at $26.91, while CERN trades at $94.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas CERN's P/E ratio is 55.84. In terms of profitability, MTBCP's ROE is +0.17%, compared to CERN's ROE of +0.14%. Regarding short-term risk, MTBCP is more volatile compared to CERN. This indicates potentially higher risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, MTBC comparison data is unavailable. Regarding current trading prices, MTBCP is priced at $26.91, while MTBC trades at $3.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas MTBC's P/E ratio is N/A. In terms of profitability, MTBCP's ROE is +0.17%, compared to MTBC's ROE of +0.17%. Regarding short-term risk, MTBCP is less volatile compared to MTBC. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, MTBCO comparison data is unavailable. Regarding current trading prices, MTBCP is priced at $26.91, while MTBCO trades at $25.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas MTBCO's P/E ratio is N/A. In terms of profitability, MTBCP's ROE is +0.17%, compared to MTBCO's ROE of +0.17%. Regarding short-term risk, MTBCP is more volatile compared to MTBCO. This indicates potentially higher risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, MSPRV comparison data is unavailable. Regarding current trading prices, MTBCP is priced at $26.91, while MSPRV trades at $0.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas MSPRV's P/E ratio is N/A. In terms of profitability, MTBCP's ROE is +0.17%, compared to MSPRV's ROE of -0.35%. Regarding short-term risk, MTBCP is less volatile compared to MSPRV. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, NH comparison data is unavailable. Regarding current trading prices, MTBCP is priced at $26.91, while NH trades at $1.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas NH's P/E ratio is -0.12. In terms of profitability, MTBCP's ROE is +0.17%, compared to NH's ROE of +0.35%. Regarding short-term risk, MTBCP is less volatile compared to NH. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, CSLT comparison data is unavailable. Regarding current trading prices, MTBCP is priced at $26.91, while CSLT trades at $2.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas CSLT's P/E ratio is -37.27. In terms of profitability, MTBCP's ROE is +0.17%, compared to CSLT's ROE of -0.42%. Regarding short-term risk, MTBCP is more volatile compared to CSLT. This indicates potentially higher risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, VMCS comparison data is unavailable. Regarding current trading prices, MTBCP is priced at $26.91, while VMCS trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas VMCS's P/E ratio is N/A. In terms of profitability, MTBCP's ROE is +0.17%, compared to VMCS's ROE of +0.08%. Regarding short-term risk, MTBCP is less volatile compared to VMCS. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, SMFRW comparison data is unavailable. Regarding current trading prices, MTBCP is priced at $26.91, while SMFRW trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas SMFRW's P/E ratio is N/A. In terms of profitability, MTBCP's ROE is +0.17%, compared to SMFRW's ROE of -0.17%. Regarding short-term risk, MTBCP is less volatile compared to SMFRW. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, CHNGU comparison data is unavailable. Regarding current trading prices, MTBCP is priced at $26.91, while CHNGU trades at $73.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas CHNGU's P/E ratio is N/A. In terms of profitability, MTBCP's ROE is +0.17%, compared to CHNGU's ROE of -0.05%. Regarding short-term risk, MTBCP is less volatile compared to CHNGU. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, CHNG comparison data is unavailable. Regarding current trading prices, MTBCP is priced at $26.91, while CHNG trades at $27.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas CHNG's P/E ratio is -152.72. In terms of profitability, MTBCP's ROE is +0.17%, compared to CHNG's ROE of -0.05%. Regarding short-term risk, MTBCP is more volatile compared to CHNG. This indicates potentially higher risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, WTEQF comparison data is unavailable. Regarding current trading prices, MTBCP is priced at $26.91, while WTEQF trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas WTEQF's P/E ratio is 1.78. In terms of profitability, MTBCP's ROE is +0.17%, compared to WTEQF's ROE of N/A. Regarding short-term risk, MTBCP is more volatile compared to WTEQF. This indicates potentially higher risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, BFRGW comparison data is unavailable. Regarding current trading prices, MTBCP is priced at $26.91, while BFRGW trades at $0.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas BFRGW's P/E ratio is N/A. In terms of profitability, MTBCP's ROE is +0.17%, compared to BFRGW's ROE of -1.33%. Regarding short-term risk, MTBCP is less volatile compared to BFRGW. This indicates potentially lower risk in terms of short-term price fluctuations for MTBCP.

MTBCP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MTBCP stands at N/A. In comparison, CNVY comparison data is unavailable. Regarding current trading prices, MTBCP is priced at $26.91, while CNVY trades at $10.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MTBCP currently has a P/E ratio of N/A, whereas CNVY's P/E ratio is -71.50. In terms of profitability, MTBCP's ROE is +0.17%, compared to CNVY's ROE of -0.02%. Regarding short-term risk, MTBCP is more volatile compared to CNVY. This indicates potentially higher risk in terms of short-term price fluctuations for MTBCP.